Literature DB >> 12890146

DNA sequence profile of TP53 gene mutations in childhood B-cell non-Hodgkin's lymphomas: prognostic implications.

Claudete Esteves Klumb1, Daniel Rodrigues Furtado, Lídia Maria Magalhães de Resende, Maria Kadma Carriço, Arthur Moellman Coelho, Ernesto de Meis, Raquel Ciuvalschi Maia, Franklin David Rumjanek.   

Abstract

OBJECTIVES: The TP53 gene encodes a nuclear protein implicated in the regulation of the cell cycle, DNA repair, and apoptosis. TP53 mutations and other alterations have been described in numerous types of tumors, and some of these have been associated with poor prognosis. The aim of this study was to characterize TP53 mutations in childhood B non-Hodgkin's lymphoma, their correlation with clinical prognostic factors and response to therapy. PATIENTS AND METHODS: Samples from 49 children with B non-Hodgkin's lymphoma were examined for TP53 alterations by single-strand conformation polymorphism analysis (SSCP) of exons 5-9, direct sequencing and by p53 immunohistochemistry.
RESULTS: Mutations of TP53 were detected in 11 of 49 (22.5%) patients and more specifically in 20% of Burkitt's lymphoma. The sequence analysis showed missense mutations in 10 cases and an insertion mutation in one case. Mutations of the transition type occurred more frequently than transversions (seven of 11). Analysis of the spectrum of single-nucleotide substitutions showed a 30% frequency of transition mutations in CpG dinucleotide sequences. The overall frequency of p53 immunostaining positivity was 36% (15 of 41). There was a very good agreement between protein expression and the presence of TP53 mutation (P=0.0005). No significant correlation was found regarding age, gender, clinical stage and LDH level and TP53 mutations. Comparison of EFS curves using the log-rank test were also not significant. However, the analysis of the effects of mutations on the core p53 structure identified biological and biochemical mutants with phenotypes probably related to different response to chemotherapy.
CONCLUSIONS: Our data suggest that some types of mutants can alter the protein distinctly and may be associated with a more aggressive phenotype. In addition, the impact of TP53 mutations on response to therapy may also be influenced by disruption of other genes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12890146     DOI: 10.1034/j.1600-0609.2003.00094.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  5 in total

1.  Immunohistochemistry and scoring of Ki-67 proliferative index and p53 expression in gastric B cell lymphoma from Northern African population: a pilot study.

Authors:  Soumia Zeggai; Noria Harir; Abdelnacer Tou; Feriel Sellam; Meriem N Mrabent; Rachida Salah
Journal:  J Gastrointest Oncol       Date:  2016-06

2.  Immunohistochemical expression of transcription factors PAX5, OCT2, BCL6 and transcription regulator P53 in Non-Hodgkin lymphomas: A diagnostic cross-sectional study.

Authors:  Sawsan Ismail; Yahya Elshimali; Ali Daoud; Zuheir Alshehabi
Journal:  Ann Med Surg (Lond)       Date:  2022-05-14

3.  Mutation of the p53 tumour suppressor gene and overexpression of its protein in 62 Japanese non-Hodgkin's lymphomas.

Authors:  H Kamata; S Mitani; M Fujiwara; N Aoki; S Okada; S Mori
Journal:  Clin Exp Med       Date:  2007-07-04       Impact factor: 3.984

4.  Colorectal carcinoma prognosis can be predicted by alterations in gene p53 exons 5 and 8.

Authors:  M Vidaurreta; M L Maestro; M T Sanz-Casla; S Rafael; S Veganzones; V de la Orden; J Cerdán; M Arroyo; A Torres
Journal:  Int J Colorectal Dis       Date:  2008-03-06       Impact factor: 2.571

Review 5.  P53 abnormalities and outcomes in colorectal cancer: a systematic review.

Authors:  A J Munro; S Lain; D P Lane
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.